Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer

被引:0
作者
Seki, A
Yoshinouchi, M
Seki, N
Kodama, J
Miyagi, Y
Kudo, T
机构
[1] Okayama Univ, Sch Med, Dept Obstet & Gynecol, Okayama 700, Japan
[2] Okayama Univ, Sch Med, Dept Publ Hlth, Okayama 700, Japan
关键词
c-erbB-2; FGF-3; gene amplification; ovarian cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8% of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinicopathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, jet is not a useful prognostic marker.
引用
收藏
页码:103 / 106
页数:4
相关论文
共 21 条
[1]   ASSOCIATION OF INT2/HST1 COAMPLIFICATION IN PRIMARY BREAST-CANCER WITH HORMONE-DEPENDENT PHENOTYPE AND POOR PROGNOSIS [J].
BORG, A ;
SIGURDSSON, H ;
CLARK, GM ;
FERNO, M ;
FUQUA, SAW ;
OLSSON, H ;
KILLANDER, D ;
MCGURIE, WL .
BRITISH JOURNAL OF CANCER, 1991, 63 (01) :136-142
[2]   CHARACTERIZATION AND CHROMOSOME ASSIGNMENT OF THE HUMAN HOMOLOG OF INT-2, A POTENTIAL PROTOONCOGENE [J].
CASEY, G ;
SMITH, R ;
MCGILLIVRAY, D ;
PETERS, G ;
DICKSON, C .
MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (02) :502-510
[3]  
Csokay B, 1993, Eur J Surg Oncol, V19, P593
[4]   WHATS NEW IN BREAST-CANCER - MOLECULAR PERSPECTIVES OF CANCER DEVELOPMENT AND THE ROLE OF THE ONCOGENE C-ERBB-2 IN PROGNOSIS AND DISEASE [J].
DAWKINS, HJS ;
ROBBINS, PD ;
SMITH, KL ;
SAMA, M ;
HARVEY, JM ;
STERRETT, GF ;
PAPADIMITRIOU, JM .
PATHOLOGY RESEARCH AND PRACTICE, 1993, 189 (10) :1233-1252
[5]  
Disis ML, 1999, CLIN CANCER RES, V5, P1289
[6]  
ESTELLER M, 1995, CANCER-AM CANCER SOC, V75, P2139, DOI 10.1002/1097-0142(19950415)75:8<2139::AID-CNCR2820750817>3.0.CO
[7]  
2-6
[8]  
FRYE RA, 1989, ONCOGENE, V4, P1153
[9]   INT-2 AMPLIFICATION IN BREAST-CANCER - ASSOCIATION WITH DECREASED SURVIVAL AND RELATIONSHIP TO AMPLIFICATION OF C-ERBB-2 AND C-MYC [J].
HENRY, JA ;
HENNESSY, C ;
LEVETT, DL ;
LENNARD, TWJ ;
WESTLEY, BR ;
MAY, FEB .
INTERNATIONAL JOURNAL OF CANCER, 1993, 53 (05) :774-780
[10]   HER-2 AND INT-2 AMPLIFICATION ESTIMATED BY QUANTITATIVE PCR IN PARAFFIN-EMBEDDED OVARIAN-CANCER TISSUE SAMPLES [J].
HRUZA, C ;
DOBIANER, K ;
BECK, A ;
CZERWENKA, K ;
HANAK, H ;
KLEIN, M ;
LEODOLTER, S ;
MEDL, M ;
MULLAUERERTL, S ;
PREISER, J ;
ROSEN, A ;
SALZER, H ;
SEVELDA, P ;
SPONA, J .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (11) :1593-1597